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Abstract
Introduction: Angiomyolipoma is a common benign renal tumor composed of thick-walled blood
vessels, smooth muscle, and adipose tissue. It may be found incidentally during workup for
suspected renal disease. Although angiomyolipoma may present as a palpable, tender renal mass
with flank pain and gross or microscopic hematuria, many patients are asymptomatic.
Erythrocytosis is an unusual presentation, and malignant transformation may be suspected. This
report describes a rare case of a woman diagnosed with renal angiomyolipoma and polycythemia
vera. The report discusses the differential diagnosis using erythropoietin, erythropoietin-receptor
and Janus kinase 2.
Case presentation: A 79-year-old Chinese woman was diagnosed with erythrocytosis according
to World Health Organization criteria. An upper left renal pole angiomyolipoma was successfully
ablated after multiple phlebotomy treatments. Red cell count immediately returned to normal, but
gradually increased after 4 months. Polycythemia vera was finally diagnosed by positive mutation of
Janus kinase 2 and negative erythropoietin protein expression. Her clinical symptoms improved
with regular phlebotomy and hydroxyurea treatment.
Conclusion:  Concurrent occurence of angiomyolipoma and polycythemia vera is rare.
Polycythemia vera can be easily missed. Polycythemia vera can be confirmed with high specificity
and sensitivity by the acquired somatic mutation. Surgical intervention for this renal tumor should
be avoided unless malignancy or renal cell carcinoma is suspected or to prevent spontaneous
rupture of larger tumors.
Introduction
Polycythemia vera is a rare presentation of renal angiomy-
olipoma [1]. Angiomyolipoma is a mixed mesenchymal
tumor belonging to the family of perivascular epithelioid
cell tumors (PEComa). Renal angiomyolipoma can be
found incidentally during workup for suspected renal dis-
ease and is one of the few lesions which can be specifically
diagnosed by radiological findings. Although angiomyol-
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ipoma may present as a palpable, tender renal mass with
flank pain and gross or microscopic hematuria, many
patients are asymptomatic. Moreover, the recent discovery
of Janus kinase 2 (JAK2) V617F mutation in most patients
with polycythemia vera opens new avenues for the treat-
ment of this disease.
This report describes a rare case of a woman diagnosed
with renal angiomyolipoma and polycythemia vera and
its differential diagnosis by erythropoietin (EPO), EPO-
receptor (EPO-R) [1] and JAK2.
Case presentation
This is a case report of a 79-year-old Chinese woman with
a 5-year history of hypertension but no history of body
weight loss, systemic diseases or smoking. She had suf-
fered from palmer erythema and facial flushing associated
with itching for several years, and had undergone phle-
botomy for erythrocytosis several times before visiting our
clinic. However, due to persistent leukocytosis (169,000/
μL, normal <10,000/μL), erythrocytosis (red blood cells
7.00 million/μL, hemoglobin 18.3 g/dL, hemocrit 57.7%)
and thrombocytosis (915,000/μL), she was transferred to
the hematology department for evaluation of possible
polycythemia vera.
Red cell volume measured by Cr-51 tagged cells was
2698.2 mL (equivalent to 51.6 mL/kg; normal range: 20-
30 mL/kg). The calculated total and blood plasma vol-
umes were 5195.8 mL (equivalent to 99.5 mL/kg; normal
range: 50-75 mL/kg) and 2497.6 mL (equivalent to 47.8
mL/kg; normal range: 30-45 mL/kg), respectively. Eryth-
rocytosis was diagnosed according to criteria for absolute
erythrocytosis (female with blood plasma volume of ≥32
mL/kg and leukocyte alkaline phosphatase score of 167),
and hydroxyurea (500 mg per day) was started. Urine
vanillylmandelic acid was 7.5 mg/day (within the normal
range).
A renal echogram revealed bilateral normal-sized kidneys
as well as an oval hyperechogenic tumor (3.9 × 2.0 cm)
without acoustic shadow in the left adrenal area. Whole
body computed tomography revealed a left renal tumor
without lymphadenopathy. Left partial nephrectomy was
performed 3 months later after satisfactory control of
blood pressure. The pathology specimen was a kidney seg-
ment measuring 4.5 × 3.7 × 1.7 cm and weighing 15.2 g.
The specimen consisted almost entirely of soft, yellow
tumor. The tumor contained mature adipose tissue, thick-
walled vessels and fascicles of smooth muscle cells. The
resection margins were tumor-free.
After surgery, her hemoglobin returned to normal for 4
months and then recurrent polycythemia vera was again
treated by regular phlebotomy and hydroxyurea treat-
ment. Western blot analysis showed relatively decreased
EPO and EPO-R levels (Figure 1) in the angiomyolipoma.
Moreover, the positive JAK2 (V617F) point mutation was
demonstrated using the DNA from granulocytes in the
peripheral blood.
Primers for JAK2 (V617F) point mutation were designed
using an ARMS design program20 and included mis-
matches to maximize discrimination of the 2 alleles
(shown in lowercase) and mutant/wild-type-specific
bases. Polymerase chain reaction (PCR) primers were: for-
ward outer (FO), 5-TCCTCAGAACGTTGATGGCAG-3;
reverse outer (RO), 5-ATTGCTTTCCTTTTTCACAAGAT-3;
forward wild-type-specific (Fwt), 5-GCATTTGGTTT-
TAAATTATGGAGTATaTG-3; reverse-mutant-specific
(Rmt), 5-GTTTTACTTACTCTCGTCTCCACAaAA-3.
Discussion
Polycythemia vera is a chronic myeloproliferative disor-
der characterized (according to World Health Organiza-
tion (WHO) criteria) by clonal proliferation of myeloid
cells with variable morphologic maturity and hematopoi-
etic efficiency. Elevated red blood cell mass (RCM) distin-
guishes polycythemia vera from other myeloproliferative
disorders; but is insufficient for diagnosis. This report
describes a final diagnosis by EPO expression and JAK2
mutation [2] after clinical follow-up.
Erythrocytosis may be a secondary cause in cases associ-
ated with increased RCM or EPO-secretion. EPO is
secreted in chronic hypoxia and EPO-secreting tumors [3]
including renal cell carcinoma, hepatocellular carcinoma,
hemangioblastoma, pheochromocytoma and uterine
Western blot analysis showing reduced EPO and EPO-R  expression in this patient with angiomyolipoma and poly- cythemia vera (C1 and C2 are normal control kidney tissues,  and A is angiomyolipoma tissue) Figure 1
Western blot analysis showing reduced EPO and 
EPO-R expression in this patient with angiomyol-
ipoma and polycythemia vera (C1 and C2 are normal 
control kidney tissues, and A is angiomyolipoma tis-
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myoma. Elevated EPO is also caused by hypoxemia in
some cases of chronic pulmonary disease, shunt infection
and sleep apnea. Angiomyolipoma is a benign tumor, but
it also can demonstrate aggressive behavior and possible
malignant transformation to sarcoma, adenocarcinoma,
or renal cell carcinoma [4]. According to a previous study,
larger angiomyolipomas can be easily diagnosed by ultra-
sonography [5] or computed tomography, and highly
dense fat content within the tumor helps to make a correct
diagnosis as angiomyolipoma [6]. No angiography or fur-
ther biopsy would be needed. But some limitations of dif-
ferent diagnosis have been observed with low fat content,
or in combination with hemorrhage or necrosis.
Epithelioid angiomyolipomas are distinguished from
renal cell carcinomas by positive immunostaining for
melanoma markers and smooth muscle cell markers. In
addition, angiomyolipomas are also more commonly
associated with renal cell carcinoma in tuberous sclerosis.
The simultaneous presence of angiomyolipoma and renal
cell carcinoma has been reported [7] and in that case it
was a source of exogenous EPO secretion which was able
to be corrected [8].
Acquired or inherited mutations leading to an abnormal-
ity within the erythroid progenitors identified in poly-
cythemia vera and its rare familial variants include EPO-R
mutations, which are associated with Chuvash poly-
cythemia. Erythrocytosis has not been reported in angi-
omyolipoma [6]. Indeed, the level of EPO or EPO-R in the
reported case was not elevated, which helped exclude sec-
ondary causes of erythrocytosis.
Conclusion
Recent studies have shown that polycythemia vera can be
confirmed by the acquired somatic mutation JAK2
(V617F). This mutation is present in almost all patients
with polycythemia vera, most patients with essential
thrombocythemia and idiopathic myelofibrosis and in
some patients with atypical myeloproliferative disorder.
As in our patient, a positive JAK2 (V617F) point mutation
can be proven as 'true' polycythemia vera with high specif-
icity and sensitivity. Surgical intervention for angiomyol-
ipomas should be avoided unless malignancy or renal cell
carcinoma is suspected or to prevent spontaneous rupture
of larger tumors. The JAK2 (V617F) point mutation test is
sufficient for confirming the differential diagnosis of true
polycythemia vera before surgery, and surgical interven-
tion for angiomyolipoma should be evaluated cautiously
[9]. In this patient, we also provided EPO and EPO-R eval-
uation, which showed a reduction in levels that proved
that the angiomyolipoma was not a direct source of eryth-
rocytosis. The JAK2 (V617F) point mutation test before
surgery is very important in this situation, and we would
have performed elective biopsy for detection of EPO and
EPO-R levels if the mutation test was negative. If EPO and
EPO-R levels are negative, the patient would need to be
worked-up for other secondary causes of polycythemia
and consideration given to continued medical treatment
for polycythemia vera after surgery.
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